BR112023002004A2 - Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2 - Google Patents

Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2

Info

Publication number
BR112023002004A2
BR112023002004A2 BR112023002004A BR112023002004A BR112023002004A2 BR 112023002004 A2 BR112023002004 A2 BR 112023002004A2 BR 112023002004 A BR112023002004 A BR 112023002004A BR 112023002004 A BR112023002004 A BR 112023002004A BR 112023002004 A2 BR112023002004 A2 BR 112023002004A2
Authority
BR
Brazil
Prior art keywords
aml
treatment
hypomethylative
bcl
agonists
Prior art date
Application number
BR112023002004A
Other languages
English (en)
Inventor
Kang-Fortner Qing
M Fiore Christopher
Original Assignee
Syros Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc
Publication of BR112023002004A2 publication Critical patent/BR112023002004A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TERAPIAS PARA TRATAMENTO DE LMA E USOS DE AGONISTAS DE RARA, AGENTES HIPOMETILATIVOS E INIBIDORES DE BCL-2. A presente invenção refere-se, inter alia, a métodos de tratamento de um paciente que foi diagnosticado com leucemia mielomonocítica aguda (o subtipo M4 de LMA), leucemia monocítica aguda (o subtipo M5 de LMA), ou síndrome mielodisplásica (SMD). Os métodos incluem a administração ao paciente de uma quantidade terapeuticamente eficaz de um agonista do receptor alfa do ácido retinóico (RA-RA) ou um sal farmaceuticamente aceitável do mesmo. Em uma ou mais modalidades ( por exemplo, no tratamento de SMD), a administração do agonista de RARA ou do sal farmaceuticamente aceitável do mesmo começa antes de determinar se o paciente expressa um biomarcador RARA e/ou sem consideração do estado do biomarcador RARA.
BR112023002004A 2020-08-06 2021-08-06 Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2 BR112023002004A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063062350P 2020-08-06 2020-08-06
US202063115541P 2020-11-18 2020-11-18
US202063121760P 2020-12-04 2020-12-04
PCT/US2021/045087 WO2022032185A1 (en) 2020-08-06 2021-08-06 Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
BR112023002004A2 true BR112023002004A2 (pt) 2023-04-04

Family

ID=80117712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002004A BR112023002004A2 (pt) 2020-08-06 2021-08-06 Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2

Country Status (11)

Country Link
US (1) US20230285339A1 (pt)
EP (1) EP4192443A1 (pt)
JP (1) JP2023542273A (pt)
KR (1) KR20230087445A (pt)
CN (1) CN116209452A (pt)
AU (1) AU2021322320A1 (pt)
BR (1) BR112023002004A2 (pt)
CA (1) CA3188102A1 (pt)
IL (1) IL300369A (pt)
MX (1) MX2023001559A (pt)
WO (1) WO2022032185A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571235T3 (es) * 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
AU2016243702B2 (en) * 2015-03-31 2021-10-07 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
EP3380086B1 (en) * 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
JP7156287B2 (ja) * 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia

Also Published As

Publication number Publication date
US20230285339A1 (en) 2023-09-14
AU2021322320A1 (en) 2023-04-06
EP4192443A1 (en) 2023-06-14
MX2023001559A (es) 2023-04-05
KR20230087445A (ko) 2023-06-16
WO2022032185A1 (en) 2022-02-10
CN116209452A (zh) 2023-06-02
WO2022032185A8 (en) 2022-03-03
CA3188102A1 (en) 2022-02-10
IL300369A (en) 2023-04-01
JP2023542273A (ja) 2023-10-06

Similar Documents

Publication Publication Date Title
Irving et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial
Yu et al. The complement receptor C5aR2 promotes protein kinase R expression and contributes to NLRP3 inflammasome activation and HMGB1 release from macrophages
BR112014011670A2 (pt) anticorpo anti- adrenomedulina (adm) ou fragmento de anticorpo anti -adm ou uma estrutura anti- adm não-ig para utilização em terapia
Weisz et al. Patent ductus arteriosus ligation and adverse outcomes: causality or bias?
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
Altiparmak et al. Comparison of preoperative administration of pregabalin and duloxetine on cognitive functions and pain management after spinal surgery: a randomized, double-blind, placebo-controlled study
Misra et al. The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors
BRPI0516000A (pt) uso de um composto ou de um sal, solvato, hidrato ou isÈmero óptico farmaceuticamente aceitável do mesmo, método para tratar distúrbio bipolar em um mamìfero em necessidade do mesmo, e, kit para uso no tratamento de distúrbios bipolares
BRPI0711482A8 (pt) combinação farmacêutica que compreende 3-(3-dimetilamino-1 etil-2-metil-propil) fenol e uma nsaid
Li et al. Age and sex differences in vascular responsiveness in healthy and trauma patients: contribution of estrogen receptor-mediated Rho kinase and PKC pathways
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
BRPI0518674A2 (pt) regime de dosagem de um agonista de receptor s1p
Allais et al. Premenstrual syndrome and migraine
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
Cregan et al. KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
Balzer et al. Early administration of levosimendan is associated with improved kidney function after cardiac surgery–a retrospective analysis
BR112014016950A8 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BR112023002004A2 (pt) Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BR112014009141A8 (pt) regime de dosagem para um modulador ou agonista do receptor s1p
Özgür et al. The effect of congenital and postnatal hypothyroidism on depression-like behaviors in juvenile rats
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
Yu et al. High‐fat diet reduces neuroprotection of isoflurane post‐treatment: Role of carboxyl‐terminal modulator protein‐Akt signaling